Bristol Myers Squibb

OPDIVO

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Bristol Myers Squibb

Opdivo HCPCS:

J9299

HCPCS Code Descriptor:

Injection, nivolumab, 1 mg

Category:

J Code

Opdivo NDCs:

00003-3734-13, 00003-3756-14, 00003-3774-12, 00003-3772-11

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Opdivo CPT Codes:

-96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Opdivo:

OPDIVO is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The J Code: J9299 is aligned to the drug OPDIVO.

ACCESS PRICING AND MORE BY REGISTERING

J9299 Added Date:

January 1, 2016

J9299 Effective Date:

January 1, 2016

J9299 Termination Date:

HCPCS Active

Opdivo billing and coding information can be found through Bristol Myers Squibb at the link below:
Opdivo patient assistance information can be found through Bristol Myers Squibb Access Support at the URL: https://www.bmsaccesssupport.bmscustomerconnect.com/patient
OPDIVO prescribing information can be found at the link below:
Information regarding OPDIVO’s side effects can be found at MedlinePlus